Natco Pharma PAT at Rs 75 crore for Q1FY22
The company has strong product launches both in India and overseas
The company has strong product launches both in India and overseas
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated